To evaluate whether the therapeutic effect of the drug involved changes in the frequency of inflammatory and suppressive subsets of CD4+ T-cells, we induced colitis by the administration of DSS in the drinking water in mice treated with GSK-J4 or vehicle. Here, CD4 is linked to colitis.